Free Trial

Zacks Research Cuts Earnings Estimates for Gilead Sciences

Gilead Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research lowered its FY2026 EPS estimate to a loss of $0.86 per share from a loss of $0.65 and maintained its “Hold” rating. The revised estimate is less negative than the current consensus forecast of a $0.97 loss.
  • Gilead reported quarterly EPS of $2.55, beating the $2.19 consensus, while revenue of $8.30 billion topped estimates of $7.81 billion and rose 6.8% year over year.
  • Analyst sentiment overall remains positive: MarketBeat data showed a “Moderate Buy” consensus rating and an average price target of $171.07.
  • MarketBeat previews top five stocks to own in December.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Investment analysts at Zacks Research reduced their FY2026 earnings estimates for Gilead Sciences in a research report issued to clients and investors on Thursday, November 12th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn ($0.86) per share for the year, down from their prior estimate of ($0.65). Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Gilead Sciences' Q4 2026 earnings at $1.31 EPS, Q4 2027 earnings at $2.58 EPS and Q1 2028 earnings at $2.16 EPS.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company's quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.47 EPS.

Other equities research analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, September 19th. Barclays reduced their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 29th. Wells Fargo & Company lifted their target price on Gilead Sciences from $165.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. BMO Capital Markets reissued an "outperform" rating and issued a $184.00 target price on shares of Gilead Sciences in a research report on Friday, October 30th. Finally, Royal Bank Of Canada upped their price target on Gilead Sciences from $126.00 to $131.00 and gave the company a "sector perform" rating in a research report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $171.07.

Get Our Latest Stock Report on Gilead Sciences

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $168.08 on Monday. The business's fifty day moving average price is $155.10 and its two-hundred day moving average price is $141.80. The firm has a market capitalization of $208.48 billion, a PE ratio of -53.19 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. Gilead Sciences has a 1-year low of $116.88 and a 1-year high of $176.58.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. BlackRock Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $15,393,785,000. State Street Corp lifted its holdings in Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company's stock valued at $7,734,099,000 after buying an additional 1,357,967 shares during the period. Amundi lifted its holdings in Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company's stock valued at $1,468,836,000 after buying an additional 1,018,976 shares during the period. Legal & General Group Plc bought a new position in Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Finally, Boston Partners boosted its stake in Gilead Sciences by 8.4% in the third quarter. Boston Partners now owns 6,523,864 shares of the biopharmaceutical company's stock valued at $970,367,000 after acquiring an additional 505,906 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the company's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the transaction, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 211,709 shares of company stock worth $35,234,427. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences's dividend payout ratio (DPR) is presently -103.80%.

Gilead Sciences News Summary

Investors following GILD have been watching these news items:

  • Positive Sentiment: Zacks Research raised several forecasts, including FY2027 EPS to $9.42 from $9.36 and FY2028 EPS to $9.69 from $9.66. It also made small upward adjustments to quarterly estimates. The revisions suggest slightly improved expectations, though the analyst’s Hold rating tempers the signal.
  • Neutral Sentiment: Gilead announced a partnership with TelevisaUnivision to promote HIV-prevention awareness at the Latin GRAMMY Awards. It may build awareness, but the announcement does not specify a direct near-term financial impact. Read More..
  • Neutral Sentiment: A broader pharmaceutical-stock article highlighted Gilead’s dividend and pipeline as defensive attributes, but offered no company-specific new financial or operating catalyst. Read More..

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Further Reading

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines